You just read:

Eli Lilly's Taltz Gaining Ground in Psoriasis Market, Leaving Novartis' Cosentyx at Risk in 2017, according to Spherix Global Insights

News provided by

Spherix Global Insights

29 Nov, 2016, 07:00 ET